.webp&w=384&q=75){kind=logo}
Loading, please wait...
Loading, please wait...
Non-valvular atrial fibrillation (NVAF) remains a significant clinical challenge for cardiologists worldwide. Research suggests that vildagliptin for atrial fibrillation may offer a novel therapeutic approach by protecting heart cells. Specifically, this dipeptidyl peptidase-4 (DPP-4) inhibitor shows potential in reducing inflammatory damage and programmed cell death. A recent 2026 study highlights the importance of specific signaling pathways in this process. Therefore, understanding these mechanisms is vital for developing better cardiovascular treatments.
Vildagliptin works by modulating the nitric oxide/soluble guanylate cyclase/cyclic guanosine monophosphate (NO/sGC/cGMP) pathway. In a recent rat model, researchers found that vildagliptin for atrial fibrillation significantly improved cardiac electrical stability. Furthermore, the drug increased levels of nitric oxide (NO) and cyclic guanosine monophosphate (cGMP). These molecules are essential for maintaining proper heart rhythm and vascular tone. Consequently, vildagliptin helps restore the balance of signaling proteins in the heart tissue.
The study compared a drug-treated group with a control group of rats with induced atrial fibrillation. Notably, the treatment group showed a longer effective refractory period (ERP) and action potential duration (APD90). Moreover, vildagliptin significantly reduced the cardiomyocyte apoptosis index (AI) and the expression of inflammatory cytokines. Researchers also observed a downregulation of phosphodiesterase 5A (PDE5A). Ultimately, these changes suggest that vildagliptin protects the heart by preventing harmful structural remodeling.
Vildagliptin reduces inflammation and cardiomyocyte apoptosis. It achieves this by modulating the NO/sGC/cGMP signaling pathway and downregulating PDE5A, which improves cardiac electrical stability.
The primary pathway involved is the nitric oxide/soluble guanylate cyclase/cyclic guanosine monophosphate (NO/sGC/cGMP) signaling system. Vildagliptin enhances this pathway to protect heart tissue.
Disclaimer: This content is for informational and educational purposes only. It does not constitute medical advice or a professional physician-patient relationship. Refer to the latest local and national guidelines for clinical practice.
References
Wang Z et al. Vildagliptin alleviates cardiomyocyte apoptosis and inflammatory responses in the treatment of non-valvular atrial fibrillation by regulating the NO/sGC/cGMP signaling pathway. Immunopharmacol Immunotoxicol. 2026 Apr 29. doi: 10.1080/08923973.2026.2639559. PMID: 42056726.
Liu X, et al. Dipeptidyl peptidase-4 inhibitor decreases the risk of atrial fibrillation in patients with type 2 diabetes: a nationwide cohort study in Taiwan. BMC Cardiovasc Disord. 2017;17(1):159.
Nicotera R, et al. Effects of Vildagliptin, a Dipeptidyl Peptidase-4 Inhibitor, on parameters of glucose metabolism and vascular markers. MDPI. 2024.
Read summarized clinical updates, watch expert medical content, and earn CME certifications right from your smartphone.
Open your smartphone camera to scan and install.
Vildagliptin shows potential in treating non-valvular atrial fibrillation by reducing inflammation and apoptosis via the NO/sGC/cGMP signaling pathway....
4 months ago
Explore the emerging role of Brixadi, an extended-release buprenorphine injection, for managing stimulant use disorder through kappa opioid receptor antagonism and steady plasma levels.
Today
A premature neonate developed upper limb compartment syndrome after uterine rupture extruded the arm through a scar defect. Conservative management with continuous monitoring yielded complete functional recovery and normal limb growth at 10-year follow-up, highlighting non-operative safety in selected cases.
Today
Dendritic cells bridge innate and adaptive immunity in myocardial infarction. This review explores their pathological roles, circulating dynamics, novel tolerogenic interventions, and how standard cardiovascular medications modulate dendritic cells to improve post-infarction myocardial repair and patient outcomes.
Today
Endoscopic posterior cervical fusion combines minimally invasive decompression, joint preparation, and rigid screw-rod fixation for atlantoaxial pathologies. Early clinical findings demonstrate solid bony union, excellent symptom relief, and minimal soft-tissue morbidity without significant vascular compromise.
Yesterday
Atherosclerosis involves extensive glycometabolic reprogramming across immune and vascular cells. This review examines how glycolysis, the pentose phosphate pathway, and lactate-driven epigenetic shifts fuel plaque vulnerability, while highlighting novel therapeutic targets like PFKFB3 and LDHA.
Today
